Clinical Trial Update: Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial completed to evaluate the safety, tolerability, and immunogenicity of the RUTI tuberculosis vaccine after one month of isoniazid treatm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Latent Tuberculosis Infection
• Tuberculosis

Drugs mentioned

• ISONIAZID (ISONIAZID)
• RUTI

Snippet

Sponsor: Archivel Farma S.L. | Conditions: Latent Tuberculosis Infection, Tuberculosis | Phase 2 | Status: COMPLETED